Cargando…

PB2232: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE

Detalles Bibliográficos
Autores principales:	Lal, A., Brown, R. C., Coates, T., Kalfa, T., Kwiatkowski, J., Brevard, J., Trenor, C., Wood, K., Sheth, S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429176/ http://dx.doi.org/10.1097/01.HS9.0000851756.51961.79

Ejemplares similares

P-055: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE
por: T., COATES, et al.
Publicado: (2022)

S103: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE PKR ACTIVATOR ETAVOPIVAT (FT-4202) IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE
por: Lal, A., et al.
Publicado: (2022)

PB2231: RATIONALE FOR THE USE OF COMBINATION CHELATION THERAPY IN PATIENTS WITH THALASSEMIA SYNDROMES OR SICKLE CELL ANEMIA: A SYSTEMATIC LITERATURE REVIEW
por: Kattamis, A., et al.
Publicado: (2022)

PB2524: TRIAL IN PROGRESS: THE HIBISCUS-KIDS STUDY, A SINGLE-ARM, OPEN-LABEL, PHASE 1/2 STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF ETAVOPIVAT IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE
por: Colombatti, Raffaella, et al.
Publicado: (2023)

PB2507: EFFECTS OF TSH ON HEMOGLOBIN S POLYMERIZATION, DEFORMABILITY AND ADHESION ON SICKLE CELL ERYTHROCYTES
por: Reis, Evelyn Mendonça, et al.
Publicado: (2023)

PB2509: RED BLOOD CELL PYRUVATE KINASE PROPERTIES IN SICKLE CELL DISEASE – OF MICE AND MEN
por: Traets, Marissa, et al.
Publicado: (2023)

S109: ACTIVATION OF PYRUVATE KINASE-R WITH ETAVOPIVAT (FT-4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREATED FOR UP TO 12 WEEKS
por: Telen, M, et al.
Publicado: (2022)

PB2232: A RANDOMIZED, CONTROLLED CLINICAL TRIAL (PHASE 2B) OF NS-018 VERSUS BEST AVAILABLE THERAPY IN SUBJECTS WITH PRIMARY OR SECONDARY MYELOFIBROSIS WITH SEVERE THROMBOCYTOPENIA
por: Palacio, Melisa, et al.
Publicado: (2023)

P1495: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH
por: Saraf, S., et al.
Publicado: (2022)

O-03: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH
por: M., TELEN, et al.
Publicado: (2022)

PB2218: ASSESSMENT OF CYSTATIN C IN PEDIATRIC SICKLE CELL DISEASE AND B-THALASSEMIA AS A MARKER OF SUBCLINICAL CARDIOVASCULAR DYSFUNCTION: A CASE-CONTROL STUDY
por: Beshir, M., et al.
Publicado: (2022)

PB2503: MODULATION OF ERYTHROCYTE FUNCTION BY ENDOTHELIN-1
por: Teixeira-Alves, Lyzes Rosa, et al.
Publicado: (2023)

PB2539: GEOGRAPHICAL PREVALENCE OF THALASSEMIA GENE MUTATION IN THE PHILIPPINES
por: Velasco, Manuel Jr, et al.
Publicado: (2023)

PB2238: ΒETA-THALASSEMIA INTERMEDIA: INTERACTION OF ΑLPHA-GLOBIN GENE TRIPLICATION WITH ΒETA-THALASSEMIA HETEROZYGOUS IN SPAIN
por: Ropero, P., et al.
Publicado: (2022)

PB2544: GAUCHER-LIKE CELLS IN THALASSEMIA INTERMEDIA: IS IT A CHALLENGE?
por: Komninaka, Veroniki, et al.
Publicado: (2023)

PB2339: PROJECTED LIFETIME ECONOMIC BURDEN OF TRANSFUSION DEPENDENT BETA-THALASSEMIA IN THE UNITED STATES
por: Udeze, C., et al.
Publicado: (2022)

PB2215: GLOBAL EPIDEMIOLOGY OF SICKLE CELL DISEASE: A SYSTEMATIC LITERATURE REVIEW
por: Colombatti, R., et al.
Publicado: (2022)

PB2540: HEPATIC SAFETY PROFILE OF DEFERASIROX IN CHILDREN WITH BETA THALASSEMIA MAJOR IN OMAN
por: Almadhani, Shaimaa, et al.
Publicado: (2023)

PB2543: CIRCULATING MICROVESICLES AS POTENTIAL CELLULAR BIOMARKERS FOR THROMBOTIC RISKS IN BETA THALASSEMIA
por: Chebbi, Mariem, et al.
Publicado: (2023)

PB2029: ACQUIRED ALPHA THALASSEMIA IN ASSOCIATION WITH MYELODYSPLASTIC SYNDROME- A CASE REPORT
por: Balasubramanian, Priyavadhana, et al.
Publicado: (2023)

PB2533: FREQUENCY, PATTERN, AND CLINICAL CORRELATES OF RENAL IRON ACCUMULATION IN THALASSEMIA MAJOR
por: Meloni, Antonella, et al.
Publicado: (2023)

PB2538: FEASIBILITY AND SAFETY OF POWERPICC SOLO INSERTION THE SAPHENOUS VEIN IN CHILDREN WITH THALASSEMIA
por: Ren, Qin, et al.
Publicado: (2023)

PB2528: THE IMPACT OF ZINC SUPPLEMENTATION ON HYPERBILIRUBINEMIA IN SICKLE CELL DISEASE
por: Al Farttoosi, Mohammed
Publicado: (2023)

PB2517: OSTEOMYELITIS IN CHILDREN WITH SICKLE CELL DISEASE: IS MRI PATHOGNOMONIC?
por: Al Lawati, Murtadha, et al.
Publicado: (2023)

PB2239: DOES SIZE MATTER? THREE NEW DELETIONS IN THE HBB GENE CAUSE Β0-THALASSEMIA
por: Ropero, P., et al.
Publicado: (2022)

Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT‐4202), an Allosteric Activator of Pyruvate Kinase‐R, in Healthy Adults: A Randomized, Placebo‐Controlled, Double‐Blind, First‐in‐Human Phase 1 Trial
por: Forsyth, Sanjeev, et al.
Publicado: (2022)

PB1916: DETECTION OF AUTOANTIBODIES TO NEUTROPHIL AND ERYTHROCYTE ANTIGENS IN PATIENTS WITH CHRONIC LYMPHOPROLIFERATIVE DISEASES
por: Irina, Krobinets, et al.
Publicado: (2023)

PB2234: HEALTH LITERACY LEVEL ASSOCIATED WITH THALASSEMIA AMONG TUNISIAN’S YOUTH AND PROSPECTS FOR PRIMARY PREVENTION
por: Maaoui, F., et al.
Publicado: (2022)

PB2228: PRECISION MEDICINE IN THALASSEMIA: 30-YEAR EXPERIENCE AT SINGLE INSTITUTE FROM SAUDI ARABIA
por: Al Jaouni, S.
Publicado: (2022)

PB2546: DIAGNOSTIC POWER OF ERYTHROCYTE AND RETICULOCYTE AUTOMATIC PARAMETERS IN THE SCREENING FOR CONGENITAL HEMOLYTIC ANEMIAS
por: Bianchi, Paola, et al.
Publicado: (2023)

PB2513: A RE-AUDIT OF PAIN MANAGEMENT IN SICKLE CELL PAIN CRISES
por: Zhou, Yuhui, et al.
Publicado: (2023)

PB2216: VACUOLES APPEAR IN RED BLOOD CELLS TRANSFUSED TO PATIENTS WITH SICKLE CELL DISEASE-RELATED HYPOSPLENISM
por: Dumas, L., et al.
Publicado: (2022)

PB2221: A SYSTEMATIC LITERATURE REVIEW DESCRIBING PROTECTIVE EFFECTS OF HBF IN SICKLE CELL DISEASE OUTCOMES
por: Mitelman, O., et al.
Publicado: (2022)

PB2233: SYSTEMATIC LITERATURE REVIEW OF HEALTH-RELATED QUALITY OF LIFE BURDEN IN PATIENTS ACROSS THE SPECTRUM OF THALASSEMIA
por: Musallam, K. M., et al.
Publicado: (2022)

PB2542: MOLECULAR SPECTRUM OF ALPHA THALASSEMIA MUTATIONS IN THE WESTERN PROVINCE OF SAUDI ARABIA AND RECOMMENDATION FOR PREMARITAL SCREENING
por: Attallah, Samy, et al.
Publicado: (2023)

PB2217: SICKLE CELL DISEASE IS A RISK FACTOR FOR THE PROGRESSION AND PROGNOSIS OF COVID-19
por: Goyal, V., et al.
Publicado: (2022)

PB2504: USE OF CONSUMER WEARABLES TO MONITOR AND PREDICT PAIN IN PATIENTS WITH SICKLE CELL DISEASE
por: Vuong, Caroline, et al.
Publicado: (2023)

PB2226: THE ROLE OF COMPLEMENT IN THE IMMUNE RESPONSE OF SICKLE CELL DISEASE PATIENTS AFER COVID-19 VACCINATION
por: Varelas, C., et al.
Publicado: (2022)

PB2537: PREDICTORS OF BACTERIAL INFECTION AMONG TRANSFUSION-DEPENDENT THALASSEMIA PATIENTS IN A TERTIARY GOVERNMENT HOSPITAL IN THE PHILIPPINES
por: Baylon, Angelica Kristine, et al.
Publicado: (2023)

PB2222: THE PROTECTIVE EFFECT OF THE SPLEEN IN SICKLE CELL PATIENTS. A COMPARATIVE STUDY BETWEEN PATIENTS WITH ASPLENIA AND HYPERSPLENISM.
por: Peretz, S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oof8o60ei3qi8sjtje4epcm18n